Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9

Tuin, S.J.L. van der; Kuhnast, S.; Berbee, J.F.P.; Verschuren, L.; Pieterman, E.J.; Havekes, L.M.; ... ; Wang, Y.N. (2015)

Article / Letter to editor

• cholesteryl ester transfer protein
• cholesterol
• metabolism
• drug therapy
• hypolipidemic drugs
• low density lipoprotein
• lipids
• lipoproteins
• proprotein convertase subtilisin
• kexin type 9
• very low density lipoprotein

• All authors: Tuin, S.J.L. van der; Kuhnast, S.; Berbee, J.F.P.; Verschuren, L.; Pieterman, E.J.; Havekes, L.M.; Hoorn, J.W.A. van der; Rensen, P.C.N.; Jukema, J.W.; Princen, H.M.G.; Dijk, K.W. van; Wang, Y.N.
• Date: 2015-11-30
• Journal: Journal of Lipid Research
• Volume: 56
• Issue: 11
• Pages: 2085 - 2093
• DOI: doi:10.1194/jlr.M057794